|
V.TLT
|
Maybe delayed newsletter was to coincide with the move of their research...
|
|
V.TLT
|
Typically the newsletters have come out on a Monday, but I'd be happy for...
|
|
V.TLT
|
Each week I say, this must be the week it comes out, only to tell myself...
|
|
V.TLT
|
I didn't care for the BTD date being pushed back either, but it just must...
|
|
V.TLT
|
So BTD projected timeline was moved to end of this year, and...
|
|
V.TLT
|
Great news, but I assumed they would have started testing on animals after 10...
|
|
V.TLT
|
From March 29 news release: A Partnership with the Li Ka Shing Knowledge...
|
|
V.TLT
|
Wow, a CR of 45%, from a pill, from an unknown drug from an unknown company...
|
|
V.TLT
|
With Sesen Bio reeling from the Complete Response Letter (CRL) (issues...
|
|
V.TLT
|
One difference in this quarters newsletter, besides the improved numbers and...
|
|
V.TLT
|
This just solidified my position. It's anybody's guess where the...
|
|
V.TLT
|
Ya, if he was some yahoo that doesn't believe in science and vaccines...
|
|
V.TLT
|
Dr. Vera Madzarevic, Ph.D. will assume the role of Director of Clinical...
|
|
V.TLT
|
Seems like Urogen is treating low grade bladder cancer. I've not heard...
|
|
V.TLT
|
It's been about 6 months since the vaccine announcement, seems like there...
|
|
V.TLT
|
The OSC agreement seems to indicate 5 years, from Feb 2018, before Roger...
|
|
V.TLT
|
I'm wondering about the wording here from the previous quarterly about...
|
|
V.TLT
|
For the 27 subjects in TLTs pivotal trial to achieve the same CR rate at 360...
|
|
V.TLT
|
Not sure if this was shared, but quarterly is viewable on the website...
|
|
V.TLT
|
DJ, your numbers look accurate, and things look to be going in the right...
|